[
1. Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25:26-34.10.1016/j.cmi.2018.07.011
]Search in Google Scholar
[
2. Chakrabarti A, Sood P, Denning D. Estimating Fungal Infection Burden in India: Mucormycosis Burden as a Case Study. https://www.gaffi.org/wp-content/uploads/P1044.pdf (1 December 2020)
]Search in Google Scholar
[
3. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634-653.10.1086/432579
]Search in Google Scholar
[
4. Ferguson BJ. Mucormycosis of the nose and paranasal sinuses. Otolaryngol Clin North Am. 2000;33:349-65.10.1016/S0030-6665(00)80010-9
]Search in Google Scholar
[
5. Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis. 2004;17:517-525.10.1097/00001432-200412000-00003
]Search in Google Scholar
[
6. Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int. 1994;45:667-671.10.1038/ki.1994.89
]Search in Google Scholar
[
7. de Locht M, Boelaert JR, Schneider YJ. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol. 1994;47:1843-1850.10.1016/0006-2952(94)90314-X
]Search in Google Scholar
[
8. Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis. 1991;18:660-667.10.1016/S0272-6386(12)80606-8
]Search in Google Scholar
[
9. Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest. 1993;91:1979-1986.10.1172/JCI116419
]Search in Google Scholar
[
10. Gale GR, Welch AM. Studies of opportunistic fungi. I. Inhibition of Rhizopus oryzae by human serum. Am J Med Sci. 1961;241:604-612.10.1097/00000441-196105000-00008
]Search in Google Scholar
[
11. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020;80:388-393.10.1016/j.jinf.2020.02.016
]Search in Google Scholar
[
12. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475-481.10.1016/S2213-2600(20)30079-5
]Search in Google Scholar
[
13. Gangneux JP, Bougnoux ME, Dannaoui E, Cornet M, Zahar JR. Invasive fungal diseases during COVID-19: We should be prepared. J Mycol Med. 2020;30:100971.10.1016/j.mycmed.2020.100971
]Search in Google Scholar
[
14. Anjana RM, Deepa M, Pradeepa R, et al. ICMR-INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017;5:585-596.10.1016/S2213-8587(17)30174-2
]Search in Google Scholar
[
15. Ravani SA, Agrawal GA, Leuva PA, Modi PH, Amin KD. Rise of the phoenix: Mucormycosis in COVID-19 times. Indian J Ophthalmol. 2021;69:1563-1568.10.4103/ijo.IJO_310_21
]Search in Google Scholar
[
16. Hoenigl M, Seidel D, Carvalho A, et al. ECMM and ISHAM collaborators. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022;3:e543-e552.10.1016/S2666-5247(21)00237-8
]Search in Google Scholar
[
17. Krcméry V Jr, Matejicka F, Pichnová E, et al. Documented fungal infections after prophylaxis or therapy with wide spectrum antibiotics: relationship between certain fungal pathogens and particular antimicrobials? J Chemother. 1999;1:385-390.10.1179/joc.1999.11.5.385
]Search in Google Scholar
[
18. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007;39:425-429.10.1038/sj.bmt.170561417310132
]Search in Google Scholar
[
19. Muskett H, Shahin J, Eyres G, Harvey S, Rowan K, Harrison D. Risk factors for invasive fungal disease in critically ill adult patients: a systematic review. Crit Care. 2011;15:R287.10.1186/cc10574338866122126425
]Search in Google Scholar
[
20. Shafa S, Shamsi S, Bashar M. Indoor fungi on damp walls of buildings and their management. Dhaka University Journal of Biological Sciences. 2014;23:9-16.10.3329/dujbs.v23i1.19821
]Search in Google Scholar
[
21. Muthu V, Kumar M, Paul RA, et al. Is there an association between zinc and COVID-19-associated mucormycosis? Results of an experimental and clinical study. Mycoses. 2021;64:1291-1297.10.1111/myc.13365866193134420245
]Search in Google Scholar
[
22. Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Chen SC, Kong DCM. Contemporary management and clinical outcomes of mucormycosis: A systematic review and meta-analysis of case reports. Int J Antimicrob Agents. 2019;53:589-597.10.1016/j.ijantimicag.2019.01.00230639526
]Search in Google Scholar
[
23. Chakrabarti A, Singh R. Mucormycosis in India: unique features. Mycoses. 2014;57:85-90.10.1111/myc.1224325187095
]Search in Google Scholar
[
24. Machouart M, Larché J, Burton K, et al. Genetic identification of the main opportunistic Mucorales by PCR-restriction fragment length polymorphism. J Clin Microbiol. 2006;44:805-810.10.1128/JCM.44.3.805-810.2006139311716517858
]Search in Google Scholar
[
25. Hammond SP, Bialek R, Milner DA, Petschnigg EM, Baden LR, Marty FM. Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol. 2011;49:2151-2153.10.1128/JCM.00256-11312274621508149
]Search in Google Scholar
[
26. Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012;54:S55-60.10.1093/cid/cir86822247446
]Search in Google Scholar
[
27. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009;48:1743-1751.10.1086/599105280921619435437
]Search in Google Scholar
[
28. Farmakiotis D, Kontoyiannis DP. Mucormycoses. Infect Dis Clin North Am. 2016;30:143-163.10.1016/j.idc.2015.10.01126897065
]Search in Google Scholar
[
29. Sun HY, Aguado JM, Bonatti H, et al. Zygomycosis Transplant Study Group. Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am J Transplant. 2009;9:2166-2171.10.1111/j.1600-6143.2009.02754.x19681829
]Search in Google Scholar
[
30. Sun HY, Forrest G, Gupta KL, et al. Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients. Transplantation. 2010;90:85-92.10.1097/TP.0b013e3181dde8fc
]Search in Google Scholar
[
31. McCarthy M, Rosengart A, Schuetz AN, Kontoyiannis DP, Walsh TJ. Mold infections of the central nervous system. N Engl J Med. 2014;371:150-160.10.1056/NEJMra1216008484046125006721
]Search in Google Scholar
[
32. Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19:e405-e421.
]Search in Google Scholar
[
33. Noxafil (posaconazole) injection for intravenous use, delayed-release tablets for oral use,oral-suspension,prescribing-information. https://www.merck.com/product/usa/pi_circulars/n/noxafil/noxafil_pi.pdf
]Search in Google Scholar
